Ipsen Bylvay Fails Phase 3 BOLD in Biliary Atresia

Ipsen (Euronext Paris: IPN; ADR: IPSEY) announced on July 24, 2026 that the Phase 3 BOLD trial of Bylvay (odevixibat) in pediatric biliary atresia did not meet its primary endpoint of improvement in native liver survival versus placebo at week 104. This was the first global Phase 3 trial ever conducted in biliary atresia, the leading cause of pediatric liver transplantation worldwide.

The IPSEY ADR closed at $44.81 on July 24 with volume of just 229 shares, reflecting the thin OTC trading typical of foreign pharma ADRs. Most trading occurs on Euronext Paris under IPN. Ipsen is not a US-listed company, so there is no direct US ticker to track for most biotech investors.

What the trial showed

BOLD (NCT04336722) enrolled 254 patients across 19 countries. Children who had already undergone a Kasai hepatoportoenterostomy, the surgical procedure used to restore bile flow in biliary atresia, received oral odevixibat 120 mcg/kg/day or placebo once daily for up to 104 weeks. The primary endpoint was native liver survival, defined as time from randomization to first occurrence of liver transplant or death at week 104. Bylvay did not improve native liver survival compared to placebo. Safety was in line with the established profile of odevixibat in its approved indications.

Why this matters

Biliary atresia is a rare pediatric cholestatic liver disease where bile builds up in the liver, causing progressive inflammation, fibrosis, cirrhosis, and ultimately liver failure if untreated. Many children develop severe liver damage and require transplant before age 2. There are no approved medical treatments beyond surgery and transplant. The Kasai procedure buys time but does not cure the disease.

Bylvay is an ileal bile acid transport (IBAT) inhibitor. It works by blocking the reabsorption of bile acids in the intestine, diverting them to be excreted in feces instead. The logic for testing it in biliary atresia was that reducing bile acid reabsorption was hypothesized to lessen the cholestatic injury driving liver damage. That hypothesis did not translate into a survival benefit.

Commercial impact

Bylvay is already approved for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome pruritus, but the franchise has struggled commercially. The biliary atresia expansion was the most significant near-term growth lever for the drug. Without it, Bylvay’s commercial ceiling remains limited to current indications. Ipsen will continue to analyze subgroup data from the BOLD dataset, but the company explicitly stated the results reflect the significant challenge biliary atresia presents.

IBAT class divergence

The miss stands in contrast to GSK’s Lynavoy (linerixibat), also an IBAT inhibitor, which received a positive CHMP opinion for cholestatic pruritus in primary biliary cholangitis on July 24. The IBAT inhibitor class is having divergent outcomes across different cholestatic diseases: effective for pruritus symptoms in PBC and PFIC, but ineffective at modifying disease progression in biliary atresia. This is a reminder that mechanism does not guarantee outcomes across indications.

The risk for Ipsen shareholders is that the pipeline catalyst is gone and Bylvay’s growth story narrows. For a framework on interpreting clinical trial failures and what they mean for drug pipelines, see our guide to reading a clinical trial press release.

Sources: Ipsen press release, ClinicalTrials.gov (BOLD: NCT04336722).